Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials

被引:26
|
作者
Privitera, Michael [1 ]
Bhathal, Hari [2 ]
Wong, Matthew [3 ]
Cross, J. Helen [4 ]
Wirrell, Elaine [5 ]
Marsh, Eric D. [6 ]
Mazurkiewicz-Beldzinska, Maria [7 ]
Villanueva, Vicente [8 ]
Checketts, Daniel [9 ]
Knappertz, Volker [10 ]
VanLandingham, Kevan [10 ]
机构
[1] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[2] Neuroctr Barcelona, Teknon Med Ctr, Barcelona, Spain
[3] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[4] UCL, Great Ormond St Inst Child Hlth, Natl Inst Hlth Res, Biomed Res Ctr, London, England
[5] Mayo Clin, Rochester, MN USA
[6] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[7] Med Univ Gdansk, Gdansk, Poland
[8] Univ & Polytech Hosp La Fe, Valencia, Spain
[9] GW Res Ltd, Cambridge, England
[10] Greenwich Biosci Inc, Carlsbad, CA USA
关键词
antiepileptic drug; antiseizure medication; childhood onset epilepsy; drop seizures; treatment‐ resistant epilepsy;
D O I
10.1111/epi.16878
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo-controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox-Gastaut syndrome. Methods Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated. Results Overall, 235 patients received CBD (CBD10 [GWPCARE3 only], n = 67; CBD20 [pooled GWPCARE3&4], n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6-48.0). Patients had previously discontinued a median (range) of six (0-28) antiepileptic drugs (AEDs) and were currently taking a median of three (0-5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in >= 50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients. Significance Treatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14-week period.
引用
收藏
页码:1130 / 1140
页数:11
相关论文
共 12 条
  • [1] Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
    Madan Cohen, Jennifer
    Checketts, Daniel
    Dunayevich, Eduardo
    Gunning, Boudewijn
    Hyslop, Ann
    Madhavan, Deepak
    Villanueva, Vicente
    Zolnowska, Marta
    Zuberi, Sameer M.
    EPILEPSIA, 2021, 62 (09) : 2218 - 2227
  • [2] Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials
    Auvin, Stephane
    Nortvedt, Charlotte
    Fuller, Douglas S.
    Sahebkar, Farhad
    EPILEPSIA, 2023, 64 (07) : 1812 - 1820
  • [3] Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
    Lattanzi, S.
    Trinka, E.
    Russo, E.
    Striano, P.
    Citraro, R.
    Silvestrini, M.
    Brigo, F.
    DRUGS OF TODAY, 2019, 55 (03) : 177 - 196
  • [4] Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study
    Thiele, Elizabeth
    Marsh, Eric
    Mazurkiewicz-Beldzinska, Maria
    Halford, Jonathan J.
    Gunning, Boudewijn
    Devinsky, Orrin
    Checketts, Daniel
    Roberts, Claire
    EPILEPSIA, 2019, 60 (03) : 419 - 428
  • [5] Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice
    Striano, Pasquale
    McMurray, Rob
    Santamarina, Estevo
    Falip, Merce
    EPILEPTIC DISORDERS, 2018, 20 (01) : 13 - 29
  • [6] Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome
    Clements, Karen M.
    Skornicki, Michelle
    O'Sullivan, Amy K.
    EPILEPSY & BEHAVIOR, 2013, 29 (01) : 184 - 189
  • [7] Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome
    Tolbert, Dwain
    Harris, Stuart I.
    Bekersky, Ihor
    Lee, Deborah
    Isojarvi, Jouko
    EPILEPSY & BEHAVIOR, 2014, 37 : 11 - 15
  • [8] Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey
    Berg, Anne T.
    Dixon-Salazar, Tracy
    Meskis, Mary Anne
    Danese, Sherry R.
    Le, Ngoc Minh D.
    Perry, M. Scott
    EPILEPSY RESEARCH, 2024, 200
  • [9] Real-world experience of cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: Results from a retrospective multicentre chart review in Germany☆
    Strzelczyk, Adam
    Schubert-Bast, Susanne
    von Podewils, Felix
    Knake, Susanne
    Mayer, Thomas
    Klotz, Kerstin Alexandra
    Buhleier, Elisa
    Herold, Luise
    Immisch, Ilka
    Kurlemann, Gerhard
    Rosenow, Felix
    EPILEPSY & BEHAVIOR, 2025, 166
  • [10] Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study
    Nikanorova, Marina
    Brandt, Christian
    Auvin, Stephane
    McMurray, Rob
    EPILEPSY & BEHAVIOR, 2017, 76 : 63 - 70